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Letters to the Editor
OpenAn integration of deep viral suppression with sequential
immune modulation (cocktail therapy) to restore antiviral
capacity: The future of chronic hepatitis B?speculate whether an ‘‘add-on’’ approach is superior to a ‘‘switch-
to’’ PegIFN alfa-2a therapy at this stage, for patients with prior
long-time exposure to NA. This point was highlighted by Zhang
and Chen. Nevertheless, these studies introduced a new approach
to combination therapy, which requires larger comparative,
prospective trials with comprehensive analyses of the immune
system to further investigate and understand its efﬁcacy and
safety.
Current data supports that monitoring of HBsAg levels may
help to predict therapeutic outcome, guide treatment options
and determine stopping rules [9]. Our OSST trial also found that
the combination of HBeAg loss and HBsAg <1500 IU/ml at the
time of switching was associated with high rates of HBeAg
seroconversion (37.5%) and HBsAg loss (25.0%) following PegIFN
alfa-2a therapy. Patients with HBsAg <200 IU/ml at week 12
had the highest likelihood of responding to PegIFN alfa-2a. These
data are consistent with previous reports, demonstrating that
HBsAg quantiﬁcation early during treatment is a useful predictor
of response in CHB patients [10]. Exploratory analyses into pre-
dictors of response were conducted using a small number of
patients, and therefore, the results should be interpreted with
caution, will require validation by large prospective trials before
incorporation into daily clinical practice. This approach will
deﬁne baseline cut-off values to permit individualizing
Fig. 1. Underlying mechanism of current treatment options and newly
developed therapeutic regimens in the treatment of CHB. Current treatment
options involve the use of NAs, which efﬁciently inhibit the HBV DNA polymerase
and thus block the viral replication pathway, and IFN which has been shown to
have both direct antiviral and immunomodulatory effects. Besides, IL-2 and GM-
CSF have been explored in the treatment of CHB as they can enhance the function
of APC and T cells. Some newly developed therapeutic regimens will appear in the
near future, including HBV entry blockers, Toll-like receptor agonists, PD1/PD1-L
pathway blockages and therapeutic vaccines, it is conceivable that use of these
additional immunomodulators rather than IFN, might be of synergic beneﬁt in the
restoration of the innate and adaptive immune responses in CHB patients.To the Editor:
We are pleased about the interest of Zhang and Chen as well as
Halfon et al. and many others in our recent publication entitled
‘‘Switching from entecavir to PegIFN alfa-2a in patients with
HBeAg-positive chronic hepatitis B: A randomized open-label
trial (OSST trial)’’ in the Journal of Hepatology.
An important question now has arisen: What is the optimal
way to combine nucleos(t)ide analogue (NA), IFN, and perhaps
potential regimens other than the two above for the better treat-
ment of chronic hepatitis B (CHB)?
CHB patients who do not experience HBeAg seroconversion
after more than one year of treatment with a potent NA may be
considered ‘‘difﬁcult to treat’’, despite having achieved HBV
DNA suppression because of the failure to seroconvert and the
high likelihood that they will require lifelong therapy. The OSST
trial enrolled subgroups of these patients and achieved a signiﬁ-
cantly higher rate of HBeAg seroconversion and, what is more
interesting, an increased rate of HBsAg loss of up to 8.5% after
an alteration of treatment strategy [1]. We believe that this study
has a practical implication as Halfon et al. has highlighted. Data
from the one year follow-up showed that response rates of HBeAg
seroconversion increased from 17.7% (11/62) at the end of treat-
ment to 38.7% (24/62) at the end of follow-up and HBsAg loss was
durable [2].
It is important for the design of future clinical trials to
understand the mechanism, regarding how the ‘‘switch-to’’ or
‘‘add-on’’ PegIFN therapy received the extra beneﬁt, compared
to the continuous ETV monotherapy. In the OSST study we
found an early signiﬁcant restoration of the impaired innate
and adaptive immune response, including Tregs, NKG2C+ NK
cells and TLR2+ monocytes in PegIFN alfa-2a responders, which
was associated with a higher probability of seroconversion and
HBsAg loss (manuscript under review). Several studies have
investigated the possibility that high levels of HBV replication
can not only actively suppress the innate immune response,
especially type I IFN induction through the action of different
viral proteins, but also extend to blocking its antiviral activity
[3–5]. Taken together, these ﬁndings provide a possible explana-
tion for the results of the OSST trial, which showed signiﬁcant
restoration in both innate and adaptive immune responses,
using ‘‘switch-to’’ PegIFNalfa therapy for patients with prior
long-term exposure to ETV.
Earlier studies, which evaluated PegIFN alfa-2a in combination
with LAM did not demonstrate signiﬁcantly improved rates of
post-treatment response in CHB patients [6]. In those studies,
PegIFN alfa-2a and a less potent NA were started simultaneously.
Recently, another concept of combination therapy, late add-on
PegIFN alfa-2a strategy, was demonstrated to have improved
response [7,8]. It seems that’’ add-on’’ combination therapy of
PegIFN alfa-2a to an ongoing NA therapy may lead to a high rate
of response. However, due to small cohort numbers, lack of a con-
trol group, different study design and inclusion criteria, we cannotJournal of Hepatology 2015 vol. 62 j 238–251
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treatment. We are pleased to learn that this hypothesis was
conﬁrmed by Halfon et al. in their clinical practice.
In summary, the combination therapy of PegIFN alfa-2a
and NA can be beneﬁcial, but the optimal strategies for com-
bination remains to be determined. With newly developed
therapeutic regimens appearing in the near future, including
cytokines, HBV entry blockers, Toll-like receptor agonists,
and therapeutic vaccines, it is conceivable that use of these
additional immunomodulators rather than IFN, might be of
synergic beneﬁt in the restoration of innate and adaptive
immune responses in CHB patients (Fig. 1). Currently two ran-
domized, multicentre, comparative and prospective clinical
trials (Endeavor and Anchor study), involving combination
therapies of IFN, NA and immunomodulators (cocktail therapy)
for NA-treated CHB patients, are under way in China to
explore this hypothesis.
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ALPPS procedure for hepatocellular carcinoma with macrovascular
thrombosis: A new opportunity?
To the Editor:
We read with interest the recent article entitled, ‘‘Surgical treat-
ment of hepatocellular carcinoma associated with hepatic vein
tumour thrombosis’’ published by Kokudo et al. [1]. We congratu-
late the authors for their study, based on an experience of over
1500 liver resections. The authors conclude that surgical treat-
ment of patients with tumour thrombosis, involving major hepa-
tic veins (mHVTT), does not differ in terms of mortality, length of
hospital stay and frequency of complications compared with
patients with microscopic invasion (pHVTT). We agree with the
authors’ conclusion. Major hepatectomy was performed in 67%
of the cases in the mHVTT group, including four where right
extended or left hepatectomy was required. We would like to
draw attention to those selected patients. Since the ﬁrst two-
staged hepatectomy reports [2], liver resection indications have
been implemented with new surgical treatments, such as the
Associating Liver Partition and Portal vein ligation for Staged hep-
atectomy (ALPPS) procedure. Vennarecci et al. [3] described the
ALPPS procedure for hepatocellular carcinoma (HCC) with major
vascular invasion and concluded that this technique may increase
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